Sertralina

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sertralina

Quick Facts

Property Description
Active Ingredient Sertraline hydrochloride (INN)
Form Tablets, Capsules, Oral Solution (Concentrate)
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI), Antidepressant
Common Use Stabilizing mood, restoring emotional balance
Origin Synthetic (chemically manufactured)

1. Defining Sertralina: An Introduction to the Active Compound

Sertralina is the generic name for a widely utilized, prescription-only medication containing the active ingredient sertraline hydrochloride. This compound is a synthetic chemical entity and provides the medication’s pharmacological effect. It is supplied for oral administration in multiple dosage forms, including scored tablets, capsules, and an oral solution concentrate. The oral solution form is noteworthy as its vehicle base includes alcohol (12%) and glycerin, a distinction requiring dilution prior to ingestion.

2. What Type of Medicine is Sertralina? (Pharmacological Classification)

Sertralina belongs to the antidepressant class of medicines, classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This classification is clinically recognized for its favorable tolerability profile compared to older-generation agents like Tricyclic Antidepressants (TCAs). The SSRI term signifies a potent and selective mechanism: the medication inhibits the reuptake of the neurotransmitter serotonin (5HT) within the Central Nervous System (CNS).

3. General Purpose and Benefit of this Antidepressant

The general purpose of this SSRI is to modulate brain chemistry to establish emotional equilibrium and improve the capacity to regulate feelings. The sustained increase in serotonin signaling provides biological support to stabilize mood. Sertraline is considered a first-line treatment foundation to reduce emotional distress and support mental balance across the general patient population. This medicine is a well-established agent for helping patients manage symptoms of emotional imbalance.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Sertralina?

Possible Side Effects and Safety Information

The safety profile of Sertralina (Sertraline hydrochloride) is classified by regulatory authorities based on clinical trial frequency and the System-Organ Class (SOC) affected. The most frequently documented adverse reactions are categorized as Very Common (occurring in 1 in 10 patients or more), and these often include nausea, dry mouth, insomnia, dizziness, headache, and ejaculation failure in males. Other Common effects include diarrhea, somnolence, tremor, and increased sweating (hyperhidrosis).

Adverse reactions are formally grouped into SOC categories, such as Gastrointestinal disorders (e.g., vomiting, constipation) and Nervous system disorders (e.g., somnolence, tremor).

Serious Adverse Reactions

Official labeling highlights the potential for Serious Adverse Reactions, which require prompt attention. These include Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like events, and the risk of Suicidal ideation and behavior, especially when treatment is initiated or the dosage is changed. Other serious risks noted are seizures, abnormal bleeding events, and hyponatraemia (low sodium levels).

Population and Time-Related Safety

Regulatory documents contain specific safety notes for certain groups. The pediatric population is associated with an increased risk of suicidal thoughts and hostility. Older adults may have an elevated risk for hyponatraemia. The risk of suicidal ideation is officially documented as being greater early in treatment or during dose adjustments. Furthermore, the medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and when to seek help

Any suspected overdosage of Sertralina should be medically treated aggressively. Deaths have been reported primarily involving overdoses taken in combination with other drugs and/or alcohol, which underscores the need for urgent medical assessment in all cases.

Documented Clinical Manifestations

Official regulatory information identifies a spectrum of symptoms following an overdose, primarily stemming from excessive serotonergic activity. These documented manifestations include:

  • CNS Effects: Somnolence, tremor, agitation, confusion, dizziness, and seizures (which may be delayed).
  • Cardiovascular Risks: Tachycardia (fast heartbeat) and serious electrical abnormalities such as QTc prolongation and reports of Torsade de Pointes.
  • Systemic Effects: Gastrointestinal disturbances (nausea and vomiting), fever, and loss of coordination.

Immediate Actions Required

Regulators emphasize the need for immediate intervention and symptomatic and supportive measures, as no specific antidote to Sertraline is known.

When to Seek Urgent Help (Label-Derived Phrasing):

  • Seek immediate medical attention.
  • Call emergency services if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
  • Contact a Poison Center or medical toxicologist for management guidance.

Required Clinical Management

Due to potential complications, ECG monitoring and continuous monitoring of vital signs are recommended. Management procedures include establishing and maintaining a clear airway, and considering activated charcoal for gastrointestinal decontamination; inducing emesis is not recommended.

Therapeutic Uses of Sertralina

Sertraline is commonly used across therapeutic domains where additional symptomatic support is needed, assisting with the management of symptoms that create noticeable interference with daily life. It is applied in conditions involving affective, anxiety, and obsessive-compulsive spectrums, including Major Depressive Disorder (MDD), Panic Disorder (PD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), Premenstrual Dysphoric Disorder (PMDD), and Obsessive-Compulsive Disorder (OCD) in both adults and children.

The overall benefit is in contributing to easing the symptom burden associated with these conditions. The medication may support a sense of emotional stability, which in turn assists with maintaining functional stability and contributing to improved comfort. “It helps manage patterns of highly intrusive, unwanted thoughts and the intense, fear-driven avoidance that can disrupt routine.”


Quick Fact: Support for Mood and Anxiety Symptoms

Symptom Category Relief Goal Clinical Context
Persistent Low Mood May assist with managing sadness and loss of interest. Relevant in conditions characterized by periods of heightened symptoms.
Excessive Apprehension Helps manage the intensity of panic attacks and fear-driven avoidance. Applied when symptoms create noticeable functional strain.
Intrusive Cognitions Helps manage the intensity of unwanted thoughts and repetitive rituals. Relevant when supportive symptom management is appropriate.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Sertralina — Official Regulatory Information

This profile outlines the regulatory rules concerning who can and cannot use Sertralina, based strictly on official governmental documentation.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults for all approved uses. Pediatric patients (ge 6 years) only for Obsessive-Compulsive Disorder (OCD).
Populations for whom use is not recommended Individuals with Severe Hepatic Impairment. Pediatric patients for indications other than OCD. Patients with unstable epilepsy.
Populations for whom use is contraindicated Patients with known hypersensitivity to sertraline. Patients receiving concomitant Monoamine Oxidase Inhibitors (MAOIs) or Pimozide. Patients receiving Disulfiram (only for the oral concentrate formulation).
Age-related eligibility rules Minimum Age: mathbf6 years for OCD. Use is not established in children under mathbf6 years for any purpose.

Eligibility Classifications (High-Level)

Category Official Regulatory Classification/Basis
Pregnancy and lactation eligibility Conditional Use. Use during pregnancy (specifically third trimester) and lactation is restricted and requires a determination that the benefit outweighs the potential risk.
Eligibility-related restrictions Caution is required for patients with Mild to Moderate Hepatic Impairment, typically mandating a lower dose. Use is restricted in patients with a history of mania or hypomania.

Connection to the overall eligibility profile

Regulatory documents define use through mandatory contraindications (prohibiting use with MAOIs or Pimozide) and restrictions based on age limits and organ function. The eligibility profile requires that all populations outside of approved adult use or pediatric OCD meet specific criteria before the medicine can be considered.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information outlines specific substance interactions for Sertraline, emphasizing certain contraindicated combinations and risk-associated co-administrations.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including MAOI-like drugs such as Linezolid and Methylene Blue injection, is strictly prohibited due to the risk of Serotonin Syndrome. A mandatory 14-day washout period must separate the use of Sertraline and an MAOI in either direction. The combination with Pimozide is also contraindicated, as Sertraline significantly increases Pimozide concentration, posing a risk of QTc prolongation.

Pharmacodynamic and Exposure-Related Interactions

Sertraline is a documented inhibitor of the enzyme CYP2D6, which may lead to increased plasma concentrations of co-administered drugs metabolized by this pathway, such as certain Type 1C Antiarrhythmics and Tricyclic Antidepressants. Co-administration with other Serotonergic Drugs (e.g., Triptans, Tramadol) is noted to increase the risk of Serotonin Syndrome. Concomitant use with agents that affect platelet function, including NSAIDs, Aspirin, or Warfarin, carries an officially documented increased risk of bleeding events.

Substance and Population Notes

The Sertraline Oral Concentrate is contraindicated with Disulfiram due to its inherent alcohol content. Caution is advised with St. John’s Wort due to enhanced serotonergic effects. Patients with Hepatic Impairment exhibit reduced Sertraline clearance, leading to significantly increased exposure.

Mechanism of Action

Selective Serotonin Reuptake Inhibition

Sertraline's core mechanism is the selective inhibition of the Serotonin Transporter (SERT) protein. By blocking SERT, the drug prevents the reabsorption of the neurotransmitter serotonin (5-HT) back into the presynaptic neuron, thereby immediately increasing its concentration and extending its signaling time in the synaptic cleft. This molecular action establishes a foundation for subsequent long-term changes in the serotonergic system.

Neuroplastic Adaptation and Pathway Regulation

The sustained elevation of serotonin leads to a gradual process of neuroplastic adaptation where the postsynaptic nerve cells alter their sensitivity and number of receptors. This slow adaptation, which involves the desensitization of autoreceptors, fundamentally remodels the function of the serotonergic pathway. This mechanism results in changes to neural communication patterns that reflect an altered homeostatic state over several weeks, leading to the resulting system-level consequences.

sigma1 Receptor Modulation and Cellular Resilience

Sertraline also binds with high affinity to the Sigma-1 receptor (sigma1 Receptor), an action independent of its SERT inhibition. This interaction modulates intracellular signaling and cellular resilience pathways within the neuron. This distinct mechanism contributes to changes in neuronal structural integrity and function.

Dosage and Administration Information

Instruction Map: How to use Sertralina — Administration Guidelines

This map summarizes the administration instructions for sertraline.


Administration Scope

Feature General Instruction
Route of Administration Oral administration only (Tablets, Capsules, Oral Solution Concentrate).
Dosing Schedule Initial adult doses are 25 mg/day or 50 mg/day. The dose is typically adjusted in 25 mg or 50 mg increments at weekly intervals, up to a maximum recommended dose of 200 mg/day.
Timing in relation to meals Tablets may be taken with or without food.
Preparation Requirements The Oral Solution Concentrate (20 mg/mL) must be immediately diluted in 4 ounces (1/2 cup) of water, ginger ale, lemon-lime soda, lemonade, or orange juice.
Age-Group Administration Rules Pediatric (OCD): Starts at 25 mg (ages 6-12) or 50 mg (ages 13-17). Hepatic Impairment: Requires half the recommended starting and maximum dosage.
Missed-Dose Rules Take the missed dose as soon as remembered, but if it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not take a double dose.
Special Procedural Conditions Treatment for PMDD may follow a continuous (daily) or intermittent (luteal phase only) dosing pattern.

Instruction Classifications (High-Level)

Classification Pattern
Administration method type Oral (tablet, capsule, or diluted solution).
Frequency pattern Once daily (q.d.), with an optional intermittent regimen for PMDD.
Standard basis Follows established administration protocols.
Use-context constraints Requires titration over weekly intervals; liquid form requires dilution with specified liquids.

Resulting Procedural Structure

Step sequence (Dosing & Intake):

  • The medication is initiated at the specific oral starting dose appropriate for the condition.
  • If the oral concentrate is used, it must be immediately mixed with one of the approved diluents.
  • The dose is gradually increased in 25 mg or 50 mg increments after intervals of 7 days until the maximum dose of 200 mg/day is reached or therapeutic level is achieved.

Connection to the overall use protocol: The usage protocol defines a structured, oral-only method of administration, mandating a specific once-daily frequency and adherence to strict initial and maximum dose limits. This structure is built around a required weekly titration schedule and includes explicit conditions for adjusting the dose in specific populations and for preparing the liquid formulation.

Recent Clinical Evidence

Sertraline is a selective serotonin reuptake inhibitor (SSRI) commonly studied for use in major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), and social anxiety disorder (SAD).


Efficacy and Symptom Response

Response Timeline: Clinical trial analyses, such as those from the PANDA randomized controlled trial, suggest that the beneficial effects of sertraline on anxiety symptoms and emotional symptoms of depression (such as low mood and self-loathing) may be observed as early as two weeks after starting treatment. This is often earlier than the observed response time for overall depressive symptom severity scores, which may not show significant improvement compared to placebo until 12 weeks of use.

Core Findings: Research has consistently found that sertraline shows greater patient-reported improvement in overall mental health and quality of life measures compared to placebo across multiple conditions.

Condition Studied Key Study Outcome
Major Depressive Disorder Improvements in core emotional symptoms may appear within 2 weeks.
Anxiety/Panic/PTSD Significant improvement in generalized anxiety and associated symptoms are commonly reported.

Tolerability and Specific Populations

Tolerability Profile: In pooled data from placebo-controlled trials, the most commonly reported adverse reactions include nausea, diarrhea, insomnia, dry mouth, and decreased libido. These side effects are frequently reported early in treatment, with some, like somatic (physical) symptoms, potentially stabilizing after six weeks as emotional improvements continue.

Special Populations: While established for adult use across multiple indications, the safety and effectiveness of sertraline have not been established for children and adolescents other than those with OCD. Studies involving patients with heart failure have evaluated its use in concurrent depression, but these trials did not show a greater reduction in depression severity compared to placebo in that specific population.

Frequently Asked Questions (FAQ)

Common questions about Sertralina (FAQ)

Q: Is weight gain a common side effect associated with long-term use of Sertralina?

A: Regulatory information indicates that changes in weight may occur while taking this medication. While minimal average weight loss (1-2 lbs) was observed in controlled trials, weight change is noted. Official regulatory lists for common side effects do not typically include weight gain.

Q: What are the initial, first-week side effects people commonly report when starting Sertralina?

A: Official safety information notes that monitoring for new or worsening symptoms is important, especially when beginning treatment or after a dose change. These monitored symptoms may include increased anxiety, agitation, restlessness, and insomnia (difficulty sleeping) early in the treatment course.

Q: What is Serotonin Syndrome, and how likely is it to happen when taking Sertralina?

A: Serotonin Syndrome is a serious, potentially life-threatening event related to high serotonin activity. Symptoms can involve changes in mental status, involuntary muscle movements, and autonomic instability (such as changes in heart rate or blood pressure). It is a serious risk, and patients should be aware that it requires prompt medical evaluation.

Q: Does taking Sertralina increase the risk of bleeding or bruising?

A: Official safety information notes that Sertraline may increase the potential for bleeding or bruising. This risk is documented to increase when Sertraline is used alongside other medicines that affect blood clotting, such as NSAIDs, aspirin, or warfarin.

Q: Is the liquid form of Sertralina (oral concentrate) mixed with water or other liquids?

A: The Oral Solution Concentrate must be diluted immediately before ingestion according to official administration instructions. These instructions specifically list water, ginger ale, lemon-lime soda, lemonade, or orange juice for use. The official instructions only list these specific liquids for use as diluents.

Q: Is there a link between Sertralina and low sodium levels in the blood (hyponatremia)?

A: Yes, hyponatremia (a low level of sodium in the blood) has been reported as a potential serious adverse reaction with Sertraline. Official safety information indicates that older adults may have an elevated risk for this condition.

Q: Is it true that Sertralina can cause tremors or shaking?

A: Yes, official adverse reaction reports list tremor, or shaking, as a common side effect of the medication.

Q: Why is Sertralina sometimes preferred over older classes of antidepressants?

A: Sertraline belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class of medicines. Regulatory and clinical texts generally recognize the SSRI class for having a more favorable tolerability profile compared to older antidepressant types, such as Tricyclic Antidepressants (TCAs).

Q: How long does Sertralina stay in your system after you stop taking it?

A: According to official pharmacokinetic data, the average half-life (the time it takes for half the medication to be eliminated from the body) is approximately 26 hours. Based on this, it typically takes about one week for the drug to be cleared from the system.

Q: Can Sertralina cause problems with sleep, such as insomnia or vivid dreams?

A: Official information lists both insomnia (difficulty sleeping) and somnolence (sleepiness) as common side effects. While some individuals report vivid dreams, this specific effect is not routinely listed among the most common categories of official adverse reactions.

Q: Are sexual side effects common with Sertralina, and do they usually go away?

A: Yes, sexual side effects are common. Official adverse reaction lists include decreased libido and ejaculation failure in males as very common or common effects. Regulatory documents do not provide information on whether or when these specific side effects typically resolve.

Q: Can taking Sertralina affect a person's ability to drive or operate machinery?

A: Official safety information advises caution because Sertraline may affect coordination, judgment, or reaction time. Patients are generally advised not to drive or operate machinery until they understand how the medication affects them individually.

Q: Is it necessary to avoid grapefruit or grapefruit juice while taking Sertralina?

A: Official drug interaction information advises against using Sertraline with grapefruit or grapefruit juice. This is because grapefruit has been reported to potentially increase the concentration of the medication in the blood, which could increase the risk of side effects.

Q: Are there any herbal supplements that are dangerous to mix with Sertralina?

A: Yes, official drug interaction warnings advise specific caution with the use of the herbal supplement St. John’s Wort. This is due to the potential for enhanced serotonergic effects, which could increase the risk of Serotonin Syndrome.

Q: Is there a risk of withdrawal symptoms when stopping Sertralina, even with a slow reduction?

A: Adverse reactions known as discontinuation symptoms may occur when stopping treatment, even with a gradual dose reduction. These symptoms may include dizziness, nausea, and sensory disturbances, such as electric-shock sensations, which are reported as adverse reactions.

Q: What should be monitored by a doctor while a patient is taking Sertralina?

A: All patients should be closely monitored by a healthcare provider for any signs of clinical worsening. This includes monitoring for the emergence of suicidal thoughts and behaviors, and for symptoms of Serotonin Syndrome, especially during the initial months of treatment and following dose adjustments.

Q: Can Sertralina impact one's energy levels, making them feel more tired or more restless?

A: Official adverse reaction reports list somnolence (tiredness or sleepiness) and agitation (restlessness or uneasiness) as common side effects. These documented effects may affect an individual's perception of their energy levels.

Q: Why is it important to tell your doctor if you have a history of bipolar disorder before taking Sertralina?

A: Official safety warnings state that Sertraline can potentially trigger a manic or hypomanic episode (a period of elevated or irritable mood) in patients at risk. Safety information emphasizes that patients should be screened for a personal or family history of bipolar disorder.

Q: Can Sertralina cause a temporary increase in anxiety or agitation when first started?

A: Official safety information notes that monitoring for new or worsening anxiety or agitation is important. This is particularly noted at the beginning of treatment or when the dose is changed.

Q: Why do some people take Sertralina in the morning and others at night?

A: Sertralina is generally administered once daily. If a patient experiences side effects like somnolence (sleepiness), which is listed as a common effect, a healthcare provider may suggest taking the medication in the evening to help manage this effect.

Q: Are there any known long-term effects of taking Sertralina for several years?

A: Clinical studies have established the effectiveness of maintenance therapy with Sertralina for extended periods. However, regulatory documents do not provide a specific, finite list of risks or benefits that are uniquely tied to use beyond a few years.

Q: Does Sertralina have any impact on the risk of developing glaucoma?

A: Official information indicates that Sertralina can increase the risk of a rare, serious condition called angle-closure glaucoma. Safety information advises caution for use in patients considered at risk for this condition.

Q: What is the reported evidence for Sertralina's use in Post-Traumatic Stress Disorder (PTSD)?

A: Sertraline is officially indicated by regulatory bodies for the treatment of Posttraumatic Stress Disorder (PTSD). This indication is based on established clinical studies showing its effectiveness over a placebo for this condition.

Q: What are the signs of a potential allergic reaction to Sertralina?

A: Signs of a severe allergic reaction (hypersensitivity) may include swelling, rash, hives, or difficulty breathing. If symptoms of a severe reaction are noticed, prompt medical evaluation is necessary.

Q: Can Sertralina cause an effect known as a 'head zap' or 'brain zaps' upon discontinuation?

A: Official regulatory documents refer to these sensations as sensory disturbances, such as paresthesia or electric-shock sensations. These are documented as adverse reactions that may occur upon discontinuation of the medication.

Q: Is there scientific evidence supporting the use of Sertralina for Premenstrual Dysphoric Disorder (PMDD)?

A: Yes, Sertraline is officially indicated for the treatment of Premenstrual Dysphoric Disorder (PMDD). This indication is based on clinical trials that demonstrated its effectiveness compared to a placebo.

Q: How does Sertralina work specifically to help with Obsessive-Compulsive Disorder (OCD) symptoms?

A: The core mechanism by which Sertraline works for all its approved conditions, including Obsessive-Compulsive Disorder (OCD), is attributed to the inhibition of serotonin reuptake. This results in increased serotonin signaling in the brain.

Q: What medical conditions would typically make a person unable to take Sertralina?

A: The medication is strictly contraindicated for patients with a known hypersensitivity to Sertraline, and for those taking Monoamine Oxidase Inhibitors (MAOIs) or Pimozide. Caution or restricted use is also advised for patients with severe liver impairment, unstable epilepsy, or a history of mania/hypomania.

Q: How does Sertralina affect the feeling of being 'wired' or 'restless' in some individuals?

A: Official adverse reaction reports list agitation as a common side effect of the medication. This agitation may be experienced by some individuals as feeling 'wired' or 'restless.'

How should Sertralina be stored and disposed of?

How to Store and Dispose of Sertraline

Sertraline must be stored according to regulatory conditions to ensure its stability and potency. All forms should be stored at Controlled Room Temperature (20 C to 25 C), protecting the product from moisture, freezing, and refrigeration.

Storage Requirements

Requirement Condition
Temperature Controlled Room Temperature (20 C to 25 C)
Protection Keep tightly closed; protect from moisture; do not freeze
Container Store in the original container, out of the sight and reach of children
Oral Concentrate Discard 28 days after opening the bottle

Disposal

Unused or expired sertraline must be disposed of using an authorized drug take-back program. Regulatory guidelines prohibit disposal in wastewater or sewage. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance and sealed before discarding in household trash, and identifying information should be removed from the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sertralina found in:

A-Z Index: